CD274 and neoplasm: Perhaps, by improving the tumor microenvironment of patients receiving adjuvant atezolizumab, bevacizumab may be associated with better intracranial and extracranial progression-free survivals, especially in those patients with tumors having a PD-L1 of 1% to 49% or those found to be at high risk for brain metastases.